Kringle Pharma (4884) · TargetRestated
Using development progress as a management target
First written in FY2020. 1 of 2 entries say "Restated". Latest entry: FY2022.
2entries
3years
0from disclosures
How it moved
Same theme, other companies
Making Research and Development Progress an Evaluation Metric for Management GoalsA theme 9 companies write about · 0 as a headwind · 7 as a tailwind
The whole theme swung hardest in 2025: 2 of 8 companies on the "Worse" side.
3 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2022RestatedAnnual report
「However, we regard development progress as a management target and consider progress toward that target to be an indicator of management performance until we begin recording profits.」
The company has reiterated its view that development progress should serve as a management indicator until profits are recorded, as it has not yet reached the stage of generating recurring sales. - FY2020First statedAnnual report
「However, we regard development progress as a management target and consider progress toward that target to be an indicator of management performance until we begin recording profits.」
As the company has not yet reached the stage of recording recurring sales, it regards progress toward profit generation as a management indicator.